<DOC>
	<DOCNO>NCT00711204</DOCNO>
	<brief_summary>A 12-week , multicenter , randomize , double-blind , placebo-controlled phase IV study . Approximately 200 subject enrol , half receive active drug ( donepezil hydrochloride ) half receive match placebo approximately 50 research site within US , European Union , South Africa Australia . Eligible subject reside home , assist living facility , nurse home age 50 year old , diagnosis Alzheimer 's disease severe stage . All subject must start 5mg day ( one 5 mg tablet donepezil HCL match placebo ) . Dose increase 10 mg day ( two tablet 5 mg donepezil HCL match placebo ) 4 week . Dose may decrease base side effect . The primary efficacy measure Cornell Scale Depression Dementia ( CSDD ) . Secondary measure include Functional Assessment Staging ( FAST ) , Mini-Mental State Examination ( MMSE ) , NPI-10 ( Neuropsychiatric Inventory ) , DEMQOL Proxy ( Quality Life ) . Blood level cytokine safety also assess .</brief_summary>
	<brief_title>Evaluating The Impact Of Donepezil Hydrochloride ( Aricept ) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>1 . Age range : Patients great 50 year . 2 . Sex distribution : men woman . Women must two ( 2 ) year postmenopausal surgically sterile . 3 . MMSE score 1 12 ( inclusive ) . 4 . Clinically significant behavioral pathology measure Cornell Scale Depression Dementia ( CSDD ) , define total score CSDD 5 great least one item rat 2 ( severe ) within domain MoodRelated Signs ( Anxiety , Sadness , Lack Reactivity , Irritability ) Behavioral Disturbances ( Agitation , Retardation , Multiple Physical Complaints , Loss Interest ) . 5 . Diagnostic evidence probable possible Alzheimer 's disease ( DSMIV NINCDS/ADRDA ) make confirm site physician time screen visit . This evidence must fully document patient 's file prior baseline visit . 6 . CT MRI within last 36 month consistent diagnosis Alzheimer 's disease without clinically significant comorbid pathology find . A copy report require appended case report form . If significant change clinical status suggestive stroke possible neurological disease onset time last CT MRI screen evaluation , scan repeat consider appropriate investigator . 7 . Prior use cholinesterase inhibitor ( Aricept速 , Exelon速 , Cognex速 , Reminyl/Razadyne速 , metrifonate , physostigmine ) memantine allow , provide medication discontinue least 3 month prior screen discontinue purpose enrol patient study . 8 . Functional Assessment Staging ( FAST ) score &gt; 6a . 9 . Patients reside community , assist living facility ( ALF ) skilled nursing home . 10 . The patient must expect complete procedure schedule Screening Baseline visit include efficacy parameter . Patients must reliable caregiver family member agree accompany patient clinic visit , provide information patient require protocol , ensure compliance medication schedule . For patient reside assist live facility skilled nursing home , report caregiver may professional staff member , provide meet criteria number 11 , study visit may take place facility study site staff find preferable facilitate smooth conduct study . 11 . The caregiver must constant reliable informant minimum three day per week direct contact patient ( least 4 hour per day waking hour ) . This contact necessary ensure accurate reporting patient 's behavior . 12 . Patients stable Type I ( InsulinDependent ) Type II diabetes eligible provide monitor regularly prior study ensure adequate glucose control ( hemoglobin A1c &lt; 8 % ) . 13 . Clinical laboratory value within normal limit within sponsor 's guideline , abnormality consider clinically significant investigator sponsor . 14 . Patients controlled hypertension ( sit diastolic BP &lt; 95 mmHg and/or sit systolic BP &lt; 160 mmHg ) , right bundle branch block ( complete partial ) , pacemaker may include study . 15 . Patients thyroid disease also may include study provide euthyroid stable treatment least 3 month prior screen . 16 . Patients history seizure disorder allow provide stable treatment least 3 month seizure within past 6 month . 17 . Patients must able swallow tablet medication ; crush tablet allow . 18 . Patients independent ambulation ambulatoryaided ( i.e. , walker , cane , wheelchair ) ; vision hearing ( eyeglasses and/or hearing aid permissible ) sufficient compliance testing procedure . 19 . Patients must sufficiently proficient language assessment conduct . 1 . Age range : Patients le 50 year . 2 . MMSE score &lt; 1 &gt; 12 . 3 . FAST score &lt; 6a . 4 . CSDD &gt; 18 5 . Patients active clinically significant condition affect absorption , distribution metabolism study medication ( e.g. , inflammatory bowel disease , gastric duodenal ulcer severe lactose intolerance ) . 6 . Patients know hypersensitivity piperidine derivative cholinesterase inhibitor . 7 . Patients without reliable caregiver , patient caregiver unwilling unable complete outcome measure fulfill requirement study . 8 . Patients clinically significant obstructive pulmonary disease asthma , untreated control treatment within 3 month prior screen . 9 . Patient 's recent ( &lt; 2 year ) hematologic/oncologic disorder ( mild anemia allow ) . 10 . Evidence active , clinically significant unstable gastrointestinal , renal , hepatic , endocrine cardiovascular system disease . 11 . Patients current DSMIV diagnosis Major Depressive Disorder ( MDD ) current primary psychiatric diagnosis Alzheimer 's disease ( per DSMIV ) . Patients CSDD score &gt; 19 consider MDD exclude . 12 . Patients dementia complicate organic disease ( DSM 290.30 290.11 ) exclude ; depressive symptom delusion common Alzheimer 's disease , patient severe symptom pronounce warrant alternative , concurrent diagnosis , exclude . 13 . Patients vascular dementia dementia complicate tertiary syphilis 14 . Patients know suspected history alcoholism drug abuse ( within past 10 year ) . 15 . Any condition would make patient caregiver , opinion investigator , unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Severe</keyword>
	<keyword>Alzheimer 's Disease</keyword>
</DOC>